242 related articles for article (PubMed ID: 38005881)
1. COVID-19 Vaccines for Optimizing Immunity in the Upper Respiratory Tract.
Ramasamy R
Viruses; 2023 Oct; 15(11):. PubMed ID: 38005881
[TBL] [Abstract][Full Text] [Related]
2. Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines.
Fraser R; Orta-Resendiz A; Mazein A; Dockrell DH
Trends Mol Med; 2023 Apr; 29(4):255-267. PubMed ID: 36764906
[TBL] [Abstract][Full Text] [Related]
3. Innate and Adaptive Immune Responses in the Upper Respiratory Tract and the Infectivity of SARS-CoV-2.
Ramasamy R
Viruses; 2022 Apr; 14(5):. PubMed ID: 35632675
[TBL] [Abstract][Full Text] [Related]
4. Intranasal COVID-19 vaccines: From bench to bed.
Alu A; Chen L; Lei H; Wei Y; Tian X; Wei X
EBioMedicine; 2022 Feb; 76():103841. PubMed ID: 35085851
[TBL] [Abstract][Full Text] [Related]
5. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.
Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
Front Immunol; 2022; 13():995235. PubMed ID: 36172368
[TBL] [Abstract][Full Text] [Related]
6. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.
Americo JL; Cotter CA; Earl PL; Liu R; Moss B
Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2202069119. PubMed ID: 35679343
[TBL] [Abstract][Full Text] [Related]
7. Transmission and Protection against Reinfection in the Ferret Model with the SARS-CoV-2 USA-WA1/2020 Reference Isolate.
Patel DR; Field CJ; Septer KM; Sim DG; Jones MJ; Heinly TA; Vanderford TH; McGraw EA; Sutton TC
J Virol; 2021 Jun; 95(13):e0223220. PubMed ID: 33827954
[TBL] [Abstract][Full Text] [Related]
8. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection.
van der Ley PA; Zariri A; van Riet E; Oosterhoff D; Kruiswijk CP
Front Immunol; 2021; 12():781280. PubMed ID: 34987509
[TBL] [Abstract][Full Text] [Related]
9. Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines.
Mouro V; Fischer A
Mucosal Immunol; 2022 Apr; 15(4):584-594. PubMed ID: 35505121
[TBL] [Abstract][Full Text] [Related]
10. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
Frederiksen LSF; Zhang Y; Foged C; Thakur A
Front Immunol; 2020; 11():1817. PubMed ID: 32793245
[TBL] [Abstract][Full Text] [Related]
11. Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants.
Noor R
Viruses; 2022 Nov; 14(11):. PubMed ID: 36423150
[TBL] [Abstract][Full Text] [Related]
12. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
13. A nasal vaccine with inactivated whole-virion elicits protective mucosal immunity against SARS-CoV-2 in mice.
Tokunoh N; Tamiya S; Watanabe M; Okamoto T; Anindita J; Tanaka H; Ono C; Hirai T; Akita H; Matsuura Y; Yoshioka Y
Front Immunol; 2023; 14():1224634. PubMed ID: 37720231
[TBL] [Abstract][Full Text] [Related]
14. Do we need nasal vaccines against COVID 19 to suppress the transmission of infections?
Brüssow H
Microb Biotechnol; 2023 Jan; 16(1):3-14. PubMed ID: 36464938
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges.
Dhama K; Dhawan M; Tiwari R; Emran TB; Mitra S; Rabaan AA; Alhumaid S; Alawi ZA; Al Mutair A
Hum Vaccin Immunother; 2022 Nov; 18(5):2045853. PubMed ID: 35258416
[TBL] [Abstract][Full Text] [Related]
16. Human Nasal and Lung Tissues Infected
Alfi O; Yakirevitch A; Wald O; Wandel O; Izhar U; Oiknine-Djian E; Nevo Y; Elgavish S; Dagan E; Madgar O; Feinmesser G; Pikarsky E; Bronstein M; Vorontsov O; Jonas W; Ives J; Walter J; Zakay-Rones Z; Oberbaum M; Panet A; Wolf DG
J Virol; 2021 Jun; 95(14):e0013021. PubMed ID: 33893170
[TBL] [Abstract][Full Text] [Related]
17. Promises and challenges of mucosal COVID-19 vaccines.
Rathore APS; St John AL
Vaccine; 2023 Jun; 41(27):4042-4049. PubMed ID: 37045682
[TBL] [Abstract][Full Text] [Related]
18. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
[TBL] [Abstract][Full Text] [Related]
19. Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses.
Kim KD; Hwang I; Ku KB; Lee S; Kim SJ; Kim C
J Microbiol Biotechnol; 2020 Aug; 30(8):1109-1115. PubMed ID: 32627758
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 Vaccine: A comprehensive status report.
Kaur SP; Gupta V
Virus Res; 2020 Oct; 288():198114. PubMed ID: 32800805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
